497 related articles for article (PubMed ID: 33248210)
1. Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.
Vellichirammal NN; Chaturvedi NK; Joshi SS; Coulter DW; Guda C
Cancer Lett; 2021 Feb; 499():24-38. PubMed ID: 33248210
[TBL] [Abstract][Full Text] [Related]
2. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA-From bench to bedside.
Lim JSJ; Janku F; Yap TA
Curr Probl Cancer; 2017; 41(3):212-221. PubMed ID: 28416241
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
Chen M; Zhao H
Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
[TBL] [Abstract][Full Text] [Related]
6. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.
Salati M; Venetis K; Fassan M; Malapelle U; Pagni F; Sajjadi E; Fusco N; Ghidini M
Future Oncol; 2021 Nov; 17(33):4607-4618. PubMed ID: 34406032
[TBL] [Abstract][Full Text] [Related]
7. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
Moldogazieva NT; Zavadskiy SP; Terentiev AA
Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
[TBL] [Abstract][Full Text] [Related]
8. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
10. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
11. Liquid Biopsy to Identify Actionable Genomic Alterations.
Ou SI; Nagasaka M; Zhu VW
Am Soc Clin Oncol Educ Book; 2018 May; 38():978-997. PubMed ID: 30231331
[TBL] [Abstract][Full Text] [Related]
12. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
[No Abstract] [Full Text] [Related]
13. Evolving Significance of Tumor-Normal Sequencing in Cancer Care.
Mandelker D; Ceyhan-Birsoy O
Trends Cancer; 2020 Jan; 6(1):31-39. PubMed ID: 31952779
[TBL] [Abstract][Full Text] [Related]
14. Technical considerations for circulating tumor DNA detection in oncology.
Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
16. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
17. [Moving towards a personalized oncology: The contribution of genomic techniques and artificial intelligence in the use of circulating tumor biomarkers].
Perrier A; Hainaut P; Guenoun A; Nguyen DP; Lamy PJ; Guerber F; Troalen F; Denis JA; Boissan M
Bull Cancer; 2022 Feb; 109(2):170-184. PubMed ID: 35034786
[TBL] [Abstract][Full Text] [Related]
18. Identification and Use of Personalized Genomic Markers for Monitoring Circulating Tumor DNA.
Chen Y; George AM; Olsson E; Saal LH
Methods Mol Biol; 2018; 1768():303-322. PubMed ID: 29717450
[TBL] [Abstract][Full Text] [Related]
19. Molecular Tumor Boards in Clinical Practice.
Luchini C; Lawlor RT; Milella M; Scarpa A
Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
Devarakonda S; Sankararaman S; Herzog BH; Gold KA; Waqar SN; Ward JP; Raymond VM; Lanman RB; Chaudhuri AA; Owonikoko TK; Li BT; Poirier JT; Rudin CM; Govindan R; Morgensztern D
Clin Cancer Res; 2019 Oct; 25(20):6119-6126. PubMed ID: 31300452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
